Adenovirus-based transfer of wild-type p53 gene increases ovarian tumor radiosensitivity

Cancer Research

Volumn 56, Issue 21, 1996, Pages 4891-4893

  Gallardo, David ^a   Drazan, Ken E ^a   McBride, William H ^a,b  

^a UCLA MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GENE PRODUCT; PROTEIN P53; VIRUS VECTOR;

ADENOVIRUS; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER RADIOTHERAPY; CANCER SIZE; CONTROLLED STUDY; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL; NONHUMAN; OVARY ADENOCARCINOMA; PRIORITY JOURNAL; RADIATION DOSE; RADIOSENSITIVITY; TUMOR SUPPRESSOR GENE;

ADENOVIRIDAE; ANIMALS; FEMALE; GENE TRANSFER TECHNIQUES; GENES, P53; HUMANS; MICE; MICE, INBRED C3H; MICE, SCID; OVARIAN NEOPLASMS; RADIATION TOLERANCE; TUMOR CELLS, CULTURED;

EID: 0029904706     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Perez, C. A., and Brady, L. W. Preface. In: Principles and Practice of Radiation Oncology Philadelphia: J. B. Lippincott Co., 1992.
2. Hall, E. J. Radiobiology for the Radiobiologist, pp. 165-182 Philadelphia: J. B. Lippincott, 1994.
3. McBride, W. H., and Dougherty G. J. Radiotherapy for genes that cause cancer. Nat. Med., 1: 1215-1217, 1995.
4. Lee, J. M., Abrahamson, J. L. A., and Berstein, A. DNA damage, oncogenesis and the p53 tumor-suppressor gene. Mut. Res., 307: 573-581, 1994.
5. Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B., and Craig, R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res., 51: 6304-6311, 1991.
6. Kastan, M. B., Canman, C. F., and Leonard, C. J. p53, cell cycle control and apoptosis: implications for cancer. Cancer Metastasis Rev., 14: 3-15, 1995.
7. Kuerbitz, S. J., Plunkett, B. S., Walsh, W., and Kastan, M. B. Wild-type p53 is a cell cycle checkpoint determinant following irradiation. Proc. Natl. Acad. Sci. USA, 89: 7491-7495, 1992.
8. Nigro, J. M., Baker, S. J., Preisinger, A. C., Jessup, J. M., Hostetter, R., Cleary, K., Bigner, S. H., Davidson, N., Baylin, S., Devilee, P., Glover, T., Collins, F. S., Weston, A., Modali, R., Harris, C. C., and Vogelstein, B Mutations in the p53 gene occur in diverse human tumour types. Nature (Lond.), 342: 705-707, 1989.
9. Liu, T., Zhang, W. W., Taylor, D. L., Roth, J. A., Goepfer, H., and Clayman, G. L. Growth suppression of human head and neck cancer cells by the introduction of a wild type p53 gene via a recombinant adenovirus. Cancer Res., 54: 3662-3667, 1994.
10. Drazan, D. E., Xiu Da, S., Csete, M. E., Zhang, W. W., Roth, J. A., Busuttil, R. W., and Shaked, A. In vivo adenoviral-mediated human p53 tumor suppressor gene transfer and expression in rat liver after resection. Surgery, 116: 197-203, 1994.
11. Toloza, E. M., Hunt, K. H., McBride, W. H., Lau, R., Pang, S., Swisher, S., Rhoades, K., Atha, T., Drake, T., Belldegrun, A., Glaspy, J., and Economou, J. S. In vivo cancer gene therapy with a recombinant interleukin-2 adenovirus vector Cancer Gene Therapy, 3: 11-17, 1996.
12. Lowe, S. W., Schmitt, E. M., Smith, S. W., Osborne, B. A., and Jacks, T. p53 is required for radiation induced apoptosis in mouse thymocytes. Nature (Lond.), 362: 847-849, 1993.
13. Fan, S., el-Diery, D. W., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A. J., Magrath, I., Kohn, K. W., and O'Connor, P. M. p53 mutations are associated with decreased sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res., 54: 5824-5830, 1994.
14. O'Connor, P. M., Jackman, J., Jondle, D., Bhatia, K., Magrath, I., and Kohn, K. Role of the p53 tumor suppressor gene in cell cycle arrest and radiosensitivity of Burkitts lymphoma cell lines Cancer Res., 53: 4776-4780, 1993.
15. Brachman, D. G., Beckett, M., Graves, D., Haraf, D., Vokes, E., and Weichselbaum, R. R. p53 mutation does not correlate with radiosensitivity in 24 head and neck cancer cell lines Cancer Res., 53: 3667-3669, 1993.
16. McIlwrath, A. J., Vasey, P. A., Ross, G., and Brown, R. Cell cycle arrests and radiosensitivity of human tumor cell lines: dependence on wild-type p53 for radiosensitivity. Cancer Res., 54: 3718-3722, 1994.
17. Gjerset, R. A., Turla, S. T., Sobol, R. E., Scalise, J. J., Mercola, D., Collins, H., and Hopkins, P. J. Use of wild-type p53 to achieve complete treatment sensitization of tumor cells expressing endogenous mutant p53. Mol. Carcinog., 14: 275-85, 1995.
18. Merzak, A., Raynal, S., Rogers, J. P., Lawrence, D., and Pilkington, G. J. Human wild type p53 inhibits cell proliferation and elicits dramatic morphological changes in human glioma cell lines in vitro. J. Neurol. Sci., 127: 125-133, 1994.
19. Akio, A., Miyagi, Y., Sugiyama, A., Gamanuma, M., Hong, S. I., Takamoto, S., Nomura, K., Matsutani, M., Takakura, K., and Kuchino, Y. Negative effects of wild type p53 and c-Myc on cellular growth and tumongenicity of glioma cells. J. Neuro-Oncol., 19: 259-268, 1994.
20. Freeman, S. M., Abbound, C. N., Whartenby, K. A., Packman, C. H., Koeplin, D. S., Moolten, F. L., and Abraham, G. N. The "bystander effect" tumor regression when a fraction of the tumor mass is genetically modified Cancer Res., 53: 5274-5283, 1993.